Carfilzomib-dexamethasone versus bortezomib-dexamethasone in relapsed or refractory multiple myeloma: updated overall survival, safety, and subgroups - Orlowski, Robert Z.; Moreau, Philippe; Niesvizky, Ruben; Ludwig, Heinz; Oriol, Albert; Chng, Wee Joo; Goldschmidt, Hartmut; Yang, Zhao; Kimball, Amy S.; Dimopoulos, Meletios A. (Clinical lymphoma, myeloma & leukemia, 2019)
Gesehen am 23.01.2020